1. Inici
  2. Publicacions
  3. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model

Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model

Data de publicació:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Martin, Guillermo
  • Luz Perez-Sirvent, Maria
  • Martinez, David
  • Orti, Guillermo
  • Algarra, Lorenzo

Grups d'Investigació

Abstract

Background Despite the prophylactic use of allopurinol, tumor lysis syndrome (TLS)- related morbidity and mortality still occur in a number of patients with acute myeloid leukemia (AML).The aim of this study was: (i) to analyze the incidence and outcome of TLS in a large series of patients with AML receiving hyperhydration and allopurinol, (ii) to identify risk factors for TLS, and (iii) to develop a prognostic scoring system for estimating individual risk of TLS. Design and Methods The study included 772 adult patients with AML receiving induction chemotherapy between 1980 and 2002. TLS was divided into laboratory TLS (LTLS) or clinical TLS (CTLS).The population study was randomly divided into training and test subsets, so that a prognostic model for CTLS was developed in one set and validated in the other. Results Overall, 130 patients (17%) developed TLS (5% CTLS and 12% LTLS). Unlike LTLS, CTLS was associated with a higher rate of death from induction therapy. Multivariate analysis showed that pretreatment serum lactate dehydrogenase (LDH) levels above laboratory normal values, creatinine >1.4 mg/dL, uric acid >7.5 mg/dL and white blood cell (WBC) counts >25x10(9)/L were independent risk factors for CTLS and LTLS. The scoring system, based on pretreatment WBC counts, and uric acid and LDH serum levels, had excellent discrimination and was accurate for predicting CTLS and LTLS. Conclusions TLS is frequently observed in AML patients during induction therapy. Only the development of CTLS had an impact on higher mortality rate from induction therapy. The scoring system derived from this study can be used to obtain an accurate estimate of the individual risk of TLS, allowing for risk-adapted prophylaxis against this complication.

Dades de la publicació

ISSN/ISSNe:
0390-6078, 1592-8721

HAEMATOLOGICA  FERRATA STORTI FOUNDATION

Tipus:
Article
Pàgines:
67-74
PubMed:
18166787
Factor d'Impacte:
1,046 SCImago ℠
Quartil:
Q1 SCImago ℠

Cites Rebudes en Web of Science: 127

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Keywords

  • tumor lysis syndrome; acute myeloid leukemia; incidence; risk factors; predictive model

Projectes associats

FUNGEMIA: EPIDEMIOLOGIA, MECANISMOS DE RESISTENCIA ANTIFUNGICA Y TIPADO MOLECULAR

090/2006- EVES - PEMAN . 2006

RED DE INVESTIGACION COOPERATIVA DE CANCER

RD06/0020/0031 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2006

ESTUDIO DE CONTROL DE COHORTES HISTÓRICO, INTERNACIONAL Y MULTICÉNTRICO PARA LA EVALUACIÓN DE LA EFICACIA Y SEGURIDAD DEL TRASPLANTE DE STEMEX®, HEMOCITOBLASTOS DE CORDON UMBILICAL Y CÉLULAS PROGENITORAS EXPANDIDAS EX VIVO, EN PACIENTES QUE PADECEN NEOPLASIAS HEMATOLÓGICAS A CONTINUACIÓN DEL TRATAMIENTO MIELOSUPRESOR.

Investigador Principal: GUILLERMO SANZ SANTILLANA

GCPNº02.01.001 . 2008

ESTUDIO MULTICENTRICO, ALEATORIZADO, ABIERTO, FASE III DE REVLIMID (LENALIDOMIDA) MÁS DEXAMETASONA (REDEX) VERSUS OBSERVACION EN PACIENTES CON MIELOMA MULTIPLE (MM) QUIESCENTE (MM SMOLDERING) CON ALTO RIESGO DE PROGRESION A MM SINTOMATICO.

Investigador Principal: ISIDRO JARQUE RAMOS

QUIREDEX . 2007

Compartir la publicació